Pfizer (PFE) PT Raised to $76 at BMO Capital, Reiterated as Top Pick, COVID 2022 Revenue Estimates Hiked to $63B from $40B
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman raised the price target on Pfizer (NYSE: PFE) to $76.00 (from $60.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
